OGEN - ORAGENICS INC
Close
0.45
0.019 4.133%
Share volume: 6,736
Last Updated: Fri 27 Dec 2024 08:23:27 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$0.43
0.02
4.31%
Fundamental analysis
22%
Profitability
25%
Dept financing
5%
Liquidity
50%
Performance
16%
Performance
5 Days
7.25%
1 Month
34.25%
3 Months
-1.26%
6 Months
-60.40%
1 Year
-92.87%
2 Year
-94.78%
Key data
Stock price
$0.45
DAY RANGE
$0.37 - $0.44
52 WEEK RANGE
$0.29 - $7.74
52 WEEK CHANGE
-$93.03
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Kimberly M. Murphy
Region: US
Website: oragenics.com
Employees: 5
IPO year: -
Issue type: Common Stock
Market: NYSE American
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: oragenics.com
Employees: 5
IPO year: -
Issue type: Common Stock
Market: NYSE American
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. NT-CoV2-1, an intranasal vaccine candidate provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries.
Recent news